Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies

Get started →

Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

10076

1

Dyne Therapeutics, Inc. Dyne Therapeutics Reports Significant Asset Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

10077

1

FAMILY OFFICE OF AMERICA, INC. Qualis Innovations Reports Significant Financial Improvements, Net Loss Narrows in Latest 10-Q Filing

Via official filing (AI summary) | 6 months ago | 0 comments

10078

1

Maiden Holdings, Ltd. Maiden Holdings Reports Significant Net Loss and Revenue Decline in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10079

1

SPRUCE BIOSCIENCES, INC. Spruce Biosciences Reports Financial Results, Implements Cost Reduction Measures, and Explores Additional Financing Options

Via official filing (AI summary) | 6 months ago | 0 comments

10080

1

ASSURED GUARANTY LTD Assured Guaranty Ltd. Reports Mixed Q3 2024 Results, Decline in Revenues and Adjusted Operating Income

Via official filing (AI summary) | 6 months ago | 0 comments

10081

1

Perimeter Solutions, Inc. Perimeter Solutions Reports 102% Net Sales Growth, Operating Loss in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10082

1

reAlpha Tech Corp. reAlpha Tech Corp. Reports 475% Revenue Growth, Operating Losses in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

10083

1

Vincerx Pharma, Inc. Vincerx Pharma Reports Significant Decrease in Cash and Cash Equivalents, Operating Expenses, and Net Loss

Via official filing (AI summary) | 6 months ago | 0 comments

10084

1

Lifeward Ltd. LifeWard Ltd. Reports 39% Revenue Growth, Narrowing Losses in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

10085

1

WERNER ENTERPRISES INC Werner Enterprises Reports Decline in Revenue and Net Income for Q3 and Nine Months of 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10086

1

HERON THERAPEUTICS, INC. /DE/ Heron Therapeutics Reports Improved Revenue and Reduced Losses in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10087

1

NEVRO CORP Nevro Corp. Reports Decline in Revenue and Profitability for Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10088

1

FEMASYS INC Femasys Inc. Reports 127% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10089

1

DZS INC. DZS Inc. Reports 67.8% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10090

1

UFP TECHNOLOGIES INC UFP Technologies Reports 44% Revenue Growth in Q3 2024, Driven by Medical Market and Strategic Acquisitions

Via official filing (AI summary) | 6 months ago | 0 comments

10091

1

CervoMed Inc. CervoMed Reports Significant Net Loss and Increased Grant Revenue in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

10092

1

Mineralys Therapeutics, Inc. Mineralys Therapeutics Reports Increased Cash Reserves, Rising Operating Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | 6 months ago | 0 comments

10093

1

GILEAD SCIENCES, INC. Gilead Sciences Reports Mixed Q3 Results with Increased Revenues and Declining Profitability

Via official filing (AI summary) | 6 months ago | 0 comments

10094

1

Assertio Holdings, Inc. Assertio Holdings Reports Decline in Revenues, Improvement in Profitability in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10095

1

SIEBERT FINANCIAL CORP Siebert Financial Reports Strong Revenue Growth and Improved Profitability in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10096

1

Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals Reports Significant Revenue Growth and Strategic Acquisitions in Latest 10-Q Filing

Via official filing (AI summary) | 6 months ago | 0 comments

10097

1

Replimune Group, Inc. Replimune Group Reports Net Loss of $53.1 Million for Q2 2024, Improves Loss Per Share

Via official filing (AI summary) | 6 months ago | 0 comments

10098

1

Ovid Therapeutics Inc. Ovid Therapeutics Reports Modest Revenue Growth, Continued Net Losses in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments

10099

1

Protara Therapeutics, Inc. Protara Therapeutics Reports Improved Financial Position, Advances Clinical Trials for Cancer and Rare Disease Treatments

Via official filing (AI summary) | 6 months ago | 0 comments

10100

1

Hour Loop, Inc Hour Loop, Inc. Reports 6.6% Revenue Growth, Net Income Turnaround in Q3 2024

Via official filing (AI summary) | 6 months ago | 0 comments